The ARSK Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of A-549 cells with disruption of the ARSK gene. This loss-of-function model eliminates functional arylsulfatase K (ARSK), a lysosomal sulfatase involved in glycosaminoglycan desulfation. The polyclonal pool preserves parental heterogeneity while providing stable ARSK perturbation for lysosomal and disease research.
The A-549 cell line, established from a 58-year-old Caucasian male with lung adenocarcinoma, is an adherent epithelial model widely employed in cancer research. It retains key characteristics of non-small cell lung cancer, including altered metabolic pathways, oncogenic signaling, and differential drug sensitivity, facilitating studies in tumor biology, epithelial cell function, and therapeutic development.
ARSK functions as a lysosomal arylsulfatase that hydrolyzes sulfate esters from glycosaminoglycans such as heparan sulfate and dermatan sulfate, as well as from sulfatides. Its transcription is activated by TFEB, a master regulator of lysosomal biogenesis, which itself is controlled by mTORC1 and MIT/TFE transcription factors. ARSK requires post-translational modification by SUMF1 to achieve enzymatic activity and partners with other lysosomal sulfatases (ARSA, ARSB) and glycosidases within the lysosome, anchored via LAMP1/2 membrane proteins. ARSK-mediated desulfation is critical for the sequential breakdown of sulfated macromolecules; its loss results in substrate buildup and lysosomal stress.
In A-549 cells, ARSK knockout disrupts lysosomal desulfation, leading to glycosaminoglycan accumulation and lysosomal dysfunction. This accumulation can trigger lysosomal stress and impair autophagy flux, as evidenced by altered levels of autophagic markers LC3 and p62. The resulting lysosomal perturbation may dysregulate mTORC1 signaling, impacting cancer cell metabolism, growth, and drug responses. Consequently, this model bridges lysosomal storage disorder pathology and lung adenocarcinoma, offering insights into how sulfatase deficiency influences cancer phenotypes.
This polyclonal knockout cell population is suited for diverse applications, including lysosomal storage disease modeling, sulfatase functional studies, and investigation of the autophagy-lysosome pathway in cancer. Representative assays include western blotting for ARSK, arylsulfatase activity assays, immunofluorescence analysis of LAMP1 and LC3, and Alcian blue staining for glycosaminoglycan accumulation. Functional cancer studies can employ MTT viability and transwell migration/invasion assays. For customized inquiries, please contact Ascent Research.
